drugset / Trial / NCT01476046

Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.

NCT01476046 ↗

Phase 1 Completed 56 enrolled GlaxoSmithKline
RandomizedSingle-groupSingle-blindDiagnostic

Summary

The main purpose of the study is to see how safe GSK1995057 is and how well it is tolerated after dosing. The study will also investigate how GSK1995057 is taken up, metabolised (chemically broken down), distributed through the body and excreted, and what some of the effects of the study drug are.

Timeline

Start
2011-03-08
Primary completion
2012-06-17
Completion
2012-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK1995057 Protein / enzyme biologic — Intravenous